Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

U.S. FDA Approves Supplemental New Drug Application (sNDA) For ERLEADA® (Apalutamide) For The Treatment Of Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

September 17, 2019
HORSHAM, Pa., Sept. 17, 2019 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the…

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

September 16, 2019
WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from its Phase…

Alexion And Bridgebio Announce Japanese License Agreement For Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

September 9, 2019
BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Sep. 9, 2019-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (NASDAQ:EIDX) today announced an agreement that grants Alexion an exclusive…